|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Du LB, Li HZ, Wang XH, Zhu C, Liu QM, Li
QL, Li XQ, Shen YZ, Zhang XP, Ying JW, et al: Analysis of cancer
incidence in Zhejiang cancer registry in China during 2000 to 2009.
Asian Pac J Cancer Prev. 15:5839–5843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qu M, Ren SC and Sun YH: Current early
diagnostic biomarkers of prostate cancer. Asian J Androl.
16:549–554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu C, Armstrong C, Zhu Y, Lou W and Gao
AC: Niclosamide enhances abiraterone treatment via inhibition of
androgen receptor variants in castration resistant prostate cancer.
Oncotarget. 7:32210–32220. 2016.PubMed/NCBI
|
|
5
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tombal B, Borre M, Rathenborg P, Werbrouck
P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J,
Baskin-Bey E, et al: Long-term efficacy and safety of enzalutamide
monotherapy in hormone-naïve prostate cancer: 1- and 2-year
open-label follow-up results. Eur Urol. 68:787–794. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beer TM, Armstrong AJ, Rathkopf DE, Loriot
Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J,
Chowdhury S, et al: Enzalutamide in metastatic prostate cancer
before chemotherapy. N Engl J Med. 371:424–433. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song C, Hu CD, Masago M, Kariyai K,
Yamawaki-Kataoka Y, Shibatohge M, Wu D, Satoh T and Kataoka T:
Regulation of a novel human phospholipase C, PLCepsilon, through
membrane targeting by Ras. J Biol Chem. 276:2752–2757. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bunney TD and Katan M: PLC regulation:
Emerging pictures for molecular mechanisms. Trends Biochem Sci.
36:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bai Y, Edamatsu H, Maeda S, Saito H,
Suzuki N, Satoh T and Kataoka T: Crucial role of phospholipase
Cepsilon in chemical carcinogen-induced skin tumor development.
Cancer Res. 64:8808–8810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang LD, Zhou FY, Li XM, Sun LD, Song X,
Jin Y, Li JM, Kong GQ, Qi H, Cui J, et al: Genome-wide association
study of esophageal squamous cell carcinoma in Chinese subjects
identifies susceptibility loci at PLCE1 and C20 or f54. Nat Genet.
42:759–763. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Fan Y, Du Z, Fan J, Hao Y, Wang J,
Wu X and Luo C: Knockdown of phospholipase Cε (PLCε) inhibits cell
proliferation via phosphatase and tensin homolog deleted on
chromosome 10 (PTEN)/AKT signaling pathway in human prostate
cancer. Med Sci Monit. 24:254–263. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Wu X, Ou L, Yang X, Wang X, Tang
M, Chen E and Luo C: PLCε knockdown inhibits prostate cancer cell
proliferation via suppression of Notch signalling and nuclear
translocation of the androgen receptor. Cancer Lett. 362:61–69.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buonamici S, Williams J, Morrissey M, Wang
A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, et al:
Interfering with resistance to smoothened antagonists by inhibition
of the PI3K pathway in medulloblastoma. Sci Transl Med.
2:51ra702010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wahid M, Jawed A, Mandal RK, Dar SA, Khan
S, Akhter N and Haque S: Vismodegib, itraconazole and sonidegib as
hedgehog pathway inhibitors and their relative competencies in the
treatment of basal cell carcinomas. Crit Rev Oncol Hematol.
98:235–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shigemura K, Huang WC, Li X, Zhau HE, Zhu
G, Gotoh A, Fujisawa M, Xie J, Marshall FF and Chung LW: Active
sonic hedgehog signaling between androgen independent human
prostate cancer cells and normal/benign but not cancer-associated
prostate stromal cells. Prostate. 71:1711–1722. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamamichi F, Shigemura K, Behnsawy HM,
Meligy FY, Huang WC, Li X, Yamanaka K, Hanioka K, Miyake H, Tanaka
K, et al: Sonic hedgehog and androgen signaling in tumor and
stromal compartments drives epithelial-mesenchymal transition in
prostate cancer. Scand J Urol. 48:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Behnsawy HM, Shigemura K, Meligy FY,
Yamamichi F, Yamashita M, Haung WC, Li X, Miyake H, Tanaka K,
Kawabata M, et al: Possible role of sonic hedgehog and
epithelial-mesenchymal transition in renal cell cancer progression.
Korean J Urol. 54:547–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lauth M, Bergstrom A, Shimokawa T and
Toftgard R: Inhibition of GLI-mediated transcription and tumor cell
growth by small-molecule antagonists. Proc Natl Acad Sci USA.
104:8455–8460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonnissen A, Isebaert S and Haustermans K:
Hedgehog signaling in prostate cancer and its therapeutic
implication. Int J Mol Sci. 14:13979–14007. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karhadkar SS, Bova GS, Abdallah N, Dhara
S, Gardner D, Maitra A, Isaacs JT, Berman DM and Beachy PA:
Hedgehog signalling in prostate regeneration, neoplasia and
metastasis. Nature. 431:707–712. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Bieber MM and Teng NN: Hedgehog
signaling regulates drug sensitivity by targeting ABC transporters
ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog.
53:625–634. 2014.PubMed/NCBI
|
|
23
|
Sims-Mourtada J, Izzo JG, Ajani J and Chao
KS: Sonic Hedgehog promotes multiple drug resistance by regulation
of drug transport. Oncogene. 26:5674–5679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh S, Chitkara D, Mehrazin R, Behrman
SW, Wake RW and Mahato RI: Chemoresistance in prostate cancer cells
is regulated by miRNAs and Hedgehog pathway. PLoS One.
7:e400212012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen M, Feuerstein MA, Levina E, Baghel
PS, Carkner RD, Tanner MJ, Shtutman M, Vacherot F, Terry S, de la
Taille A and Buttyan R: Hedgehog/Gli supports androgen signaling in
androgen deprived and androgen independent prostate cancer cells.
Mol Cancer. 9:892010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen G, Goto Y, Sakamoto R, Tanaka K,
Matsubara E, Nakamura M, Zheng H, Lu J, Takayanagi R and Nomura M:
GLI1, a crucial mediator of sonic hedgehog signaling in prostate
cancer, functions as a negative modulator for androgen receptor.
Biochem Biophys Res Commun. 404:809–815. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du Z, Li L, Sun W, Wang X, Zhang Y, Chen
Z, Yuan M, Quan Z, Liu N, Hao Y, et al: HepaCAM inhibits the
malignant behavior of castration-resistant prostate cancer cells by
downregulating Notch signaling and PF-3084014 (a gamma-secretase
inhibitor) partly reverses the resistance of refractory prostate
cancer to docetaxel and enzalutamide in vitro. Int J Oncol.
53:99–112. 2018.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gonnissen A, Isebaert S, McKee CM, Dok R,
Haustermans K and Muschel R: The hedgehog inhibitor GANT61
sensitizes prostate cancer cells to ionizing radiation both in
vitro and in vivo. Oncotarget. 7:84286–84298. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen Q, Xu R, Zeng C, Lu Q, Huang D, Shi
C, Zhang W, Deng L, Yan R, Rao H, et al: Down-regulation of Gli
transcription factor leads to the inhibition of migration and
invasion of ovarian cancer cells via integrin β4-mediated FAK
signaling. PLoS One. 9:e883862014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guerrero J, Alfaro IE, Gomez F, Protter AA
and Bernales S: Enzalutamide, an androgen receptor signaling
inhibitor, induces tumor regression in a mouse model of
castration-resistant prostate cancer. Prostate. 73:1291–1305. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hicks SN, Jezyk MR, Gershburg S, Seifert
JP, Harden TK and Sondek J: General and versatile autoinhibition of
PLC isozymes. Mol Cell. 31:383–394. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wing MR, Snyder JT, Sondek J and Harden
TK: Direct activation of phospholipase C-epsilon by Rho. J Biol
Chem. 278:41253–41258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luo XP: Phospholipase C epsilon-1 inhibits
p53 expression in lung cancer. Cell Biochem Funct. 32:294–298.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abnet CC, Freedman ND, Hu N, Wang Z, Yu K,
Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, et al: A shared
susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma
and esophageal squamous cell carcinoma. Nat Genet. 42:764–767.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Smrcka AV, Brown JH and Holz GG: Role of
phospholipase Cε in physiological phosphoinositide signaling
networks. Cell Signal. 24:1333–1343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Du HF, Ou LP, Song XD, Fan YR, Yang X, Tan
B, Quan Z, Luo CL and Wu XH: Nuclear factor-kappa B signaling
pathway is involved in phospholipase Cepsilon-regulated
proliferation in human renal cell carcinoma cells. Mol Cell
Biochem. 389:265–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang X, Ou L, Tang M, Wang Y, Wang X, Chen
E, Diao J, Wu X and Luo C: Knockdown of PLCepsilon inhibits
inflammatory cytokine release via STAT3 phosphorylation in human
bladder cancer cells. Tumour Biol. 36:9723–9732. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sharp A, Welti J, Blagg J and de Bono JS:
Targeting androgen receptor aberrations in castration-resistant
prostate cancer. Clin Cancer Res. 22:4280–4282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ardiani A, Gameiro SR, Kwilas AR, Donahue
RN and Hodge JW: Androgen deprivation therapy sensitizes prostate
cancer cells to T-cell killing through androgen receptor dependent
modulation of the apoptotic pathway. Oncotarget. 5:9335–9348. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tran C, Ouk S, Clegg NJ, Chen Y, Watson
PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al:
Development of a second-generation antiandrogen for treatment of
advanced prostate cancer. Science. 324:787–790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gonnissen A, Isebaert S and Haustermans K:
Targeting the Hedgehog signaling pathway in cancer: Beyond
smoothened. Oncotarget. 6:13899–13913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang X, Deng L, Chen Q, Wang Y, Xu R, Shi
C, Shao J, Hu G, Gao M, Rao H, et al: Inhibition of Hedgehog
signaling pathway impedes cancer cell proliferation by promotion of
autophagy. Eur J Cell Biol. 94:223–233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki
D, Lara PN Jr, DeVere White RW, Gao AC and Evans CP: Targeting
autophagy overcomes enzalutamide resistance in castration-resistant
prostate cancer cells and improves therapeutic response in a
xenograft model. Oncogene. 33:4521–4530. 2014. View Article : Google Scholar : PubMed/NCBI
|
